The COVID-19 pandemic has focused international attention on non-pharmaceutical interventions to reduce pandemic spread prior to vaccination roll-out.
General practitioners (GPs) operate out of general practices, most of which are privately owned and funded by a combination of patient fees and government subsidies.
The virus SARS-CoV-2 (the cause of COVID-19) began circulating in Wuhan, China, in November 2019. It subsequently spread across the world, becoming a global pandemic.
As the COVID-19 pandemic continues to grip the globe, there is concern for the increased vulnerability of those with chronic disease, including Parkinson’s disease (PD).
As is well-known, in December 2019 the Chinese authorities advised the World Health Organization of cases of pneumonia of unknown cause, originating in Wuhan, Hubei province.
Up to 25 September 2020, New Zealand had reported 1,829 confirmed and probable cases of COVID-19, a disease caused by a novel coronavirus originating in Wuhan, China.
The primary care response to the coronavirus disease 2019 (COVID-19) pandemic in early 2020 required significant changes by general practices throughout New Zealand.
Early in the academic year of 2020, our cohort of medical students at the University of Otago in Christchurch received a lecture on the developing COVID-19 pandemic.
Nucleic acid amplification tests (NAAT), such as reverse transcriptase PCR or transcription- mediated amplification, are the most widely used tests in New Zealand for the diagnosis of acute COVID-19 infections.
A 21-year-old man was brought in with a shotgun wound centred at the right upper thigh.
The patient, R.A., a boy of fifteen years, was admitted to Dr. Cooper’s private hospital, Eltham, complaining of pain in the lower end of the left femur. The pain was “boring” in character, worse at night, and latterly prevented him from getting sleep.